[1]周志明,曾文宏,叶芳芳.莫西沙星对慢性支气管炎急性发作期患者细菌清除率的影响[J].医学信息,2023,36(01):148-151.[doi:10.3969/j.issn.1006-1959.2023.01.031]
　ZHOU Zhi-ming,ZENG Wen-hong,YE Fang-fang.Effect of Moxifloxacin on Bacterial Clearance Rate in Patients with Acute Exacerbation of Chronic Bronchitis[J].Journal of Medical Information,2023,36(01):148-151.[doi:10.3969/j.issn.1006-1959.2023.01.031]
点击复制

莫西沙星对慢性支气管炎急性发作期患者细菌清除率的影响()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
36卷
期数:
2023年01期
页码:
148-151
栏目:
药物与临床
出版日期:
2023-01-01

文章信息/Info

Title:
Effect of Moxifloxacin on Bacterial Clearance Rate in Patients with Acute Exacerbation of Chronic Bronchitis
文章编号:
1006-1959（2023）01-0148-04
作者:
周志明; 曾文宏; 叶芳芳
（吉水县人民医院呼吸内科，江西 吉水 331600）
Author(s):
ZHOU Zhi-ming; ZENG Wen-hong; YE Fang-fang
(Department of Respiratory Medicine,Jishui County People’s Hospital,Jishui 331600,Jiangxi,China)
关键词:
慢性支气管炎急性发作; 莫西沙星; 血气分析; 细菌清除
Keywords:
Acute exacerbation of chronic bronchitis; Moxifloxacin; Blood gas analysis; Bacterial clearance
分类号:
R562.2
DOI:
10.3969/j.issn.1006-1959.2023.01.031
文献标志码:
A
摘要:
目的 探究莫西沙星对慢性支气管炎急性发作期（AECB）患者细菌清除率的影响。方法 选取2019年5月-2021年8月吉水县人民医院收治的72例AECB患者，经随机数字表法分为对照组36例，给予左氧氟沙星治疗；观察组36例，给予莫西沙星治疗。比较两组临床疗效、症状缓解时间（发热、咯痰、咳痰、气喘）、细菌清除率、血气指标[动脉血氧分压（PaO2）、动脉血二氧化碳分压（PaCO2）、血氧饱和度（SaO2）]、药物不良反应。结果 观察组临床有效率高于对照组（P＜0.05）；观察组症状缓解时间（发热、咳嗽、咳痰、气喘）短于对照组（P＜0.05）；观察组细菌总清除率高于对照组（P＜0.05）；两组治疗后PaO2、SaO2升高，PaCO2下降，且观察组PaO2、SaO2高于对照组，PaCO2低于对照组（P＜0.05）；观察组药物不良反应发生率低于对照组（P＜0.05）。结论 莫西沙星治疗AECB疗效确切，其细菌清除率高，可加快症状缓解，改善血气指标水平，且药物不良反应少。
Abstract:
Objective To investigate the effect of moxifloxacin on bacterial clearance rate in patients with acute exacerbation of chronic bronchitis (AECB).Methods A total of 72 patients with AECB admitted to Jishui County People ’s Hospital from May 2019 to August 2021 were selected and divided into control group (36 cases, received levofloxacin treatment) and treatment group (36 cases, received moxifloxacin treatment) by random number table method. The clinical efficacy, symptom relief time (fever, expectoration, expectoration, asthma), bacterial clearance rate, blood gas index [arterial partial pressure of oxygen (PaO2), arterial partial pressure of carbon dioxide (PaCO2), saturation of blood oxygen (SaO2)] and adverse drug reactions were compared between the two groups.Results The clinical effective rate of the observation group was higher than that of the control group (P<0.05). The symptom relief time (fever, cough, sputum, asthma) in the observation group was shorter than that in the control group (P<0.05). The total bacterial clearance rate of the observation group was higher than that of the control group (P<0.05). After treatment, PaO2 and SaO2 increased and PaCO2 decreased in the two groups, and PaO2 and SaO2 in the observation group were higher than those in the control group, and PaCO2 was lower than that in the control group (P<0.05). The incidence of adverse drug reactions in the observation group was lower than that in the control group (P<0.05).Conclusion Moxifloxacin is effective in the treatment of AECB, and its bacterial clearance rate is high, which can accelerate symptom relief, improve blood gas index levels, and have few adverse drug reactions.

参考文献/References:

[1]沈澜英.慢性单纯性支气管炎急性发作临床分析[J].中国急救医学,2017,37(1):14.[2]谢朝云,李耀福,蒙桂鸾,等.老年慢性支气管炎急性期住院患者多重耐药菌感染的相关因素[J].中华老年多器官疾病杂志,2020,19(7):520-524.[3]Moretti M,Lopez-Vidriero MT,Pavia D,et al.Relationship between bronchial reversibility and tracheobronchial clearance in patients with chronic bronchitis[J].Thorax,2019,52(2):176-180.[4]文永胜.氨溴索治疗慢性支气管炎急性发作的疗效及对PaO2、PaCO2的影响[J].中国医药导刊,2017,19(6):598-599.[5]陈晓红,陈秀红,陈向红.莫西沙星对老年CAP患者肺功能及血清CRP、PCT、sTREM-1水平的影响[J].贵州医科大学学报,2020,45(4):477-481.[6]徐阔,王婷,刘静,等.老年慢性支气管炎急性发作患者病原体检测结果分析[J].标记免疫分析与临床,2021,28(7):1131-1134,1145.[7]Kim V,Zhao H,Boriek AM.Persistent and Newly Developed Chronic Bronchitis Are Associated with Worse Outcomes in Chronic Obstructive Pulmonary Disease[J].Annals of the American Thoracic Society,2016,13(7):1016-1025.[8]王龙,丁群力,马红映,等.孟鲁司特联合莫西沙星治疗急性细菌性支气管炎咳嗽的临床观察[J].中国药房,2017,28(29):4096-4099.[9]Del RD,Martinez-Garcia MA,Olveira C,et al.Annual direct medical costs of bronchiectasis treatment: Impact of severity, exacerbations, chronic bronchial colonization and chronic obstructive pulmonary disease coexistence[J].Chron Respir Dis,2016,13(4):361-371.[10]陈楠,方圆,徐玲.盐酸氨溴索雾化吸入与静脉注射给药治疗慢性支气管炎急性发作的疗效与安全性研究[J].中国药物警戒,2017,14(5):262-265.[11]韩海峰.盐酸莫西沙星治疗慢性阻塞性肺疾病急性加重期的疗效及安全性[J].中国微生态学杂志,2017,29(5):577-580.[12]徐敏,胡岗,刘晓,等.头孢哌酮/舒巴坦联合莫西沙星治疗COPD合并急性下呼吸道感染临床疗效及对血清相关因子的影响[J].西部医学,2019,31(3):416-421.[13]迟岩,怀丽梅,赵鑫亮.老年慢性支气管炎呼吸道感染病原菌分布特点[J].中国病原生物学杂志,2016,11(12):1137-1139,1143.[14]张福红,王英,魏铁垒,等.美罗培南联合莫西沙星治疗慢性阻塞性肺疾病并发感染性肺炎患者肺部状态及炎性应激的影响研究[J].中华医院感染学杂志,2016,26(23):5416-5417,5479.[15]艾合提热木·塔力甫,刘甚红.班布特罗联合莫西沙星治疗慢性阻塞性肺疾病急性加重期的临床研究[J].现代药物与临床,2016,31(10):1555-1558.[16]熊天增.莫西沙星治疗慢性阻塞性肺疾病急性加重期的疗效及对细菌清除率的影响[J].四川医学,2018,39(5):582-585.[17]王瑜,王前梅,冯伟,等.莫西沙星纳米药物对耐药铜绿假单胞菌的抑菌活性及其机制[J].药学学报,2020,55(10):2460-2465.[18]Barrera CM,Mykietiuk A,Metev H,et al.Efficacy and safety of oral solithromycin versus oral moxifloxacin for treatment of community-acquired bacterial pneumonia: a global, double-blind, multicentre, randomised, active-controlled, non-inferiority trial (SOLITAIRE-ORAL)[J].Lancet Infectious Diseases,2016,16(4):421-430.[19]余晓.左氧氟沙星和莫西沙星治疗耐多药肺结核的临床疗效比较研究[J].湖南中医药大学学报,2020(2):138-140.[20]杨俊,杜春玲,卢进昌,等.莫西沙星与左氧氟沙星对慢性阻塞性肺疾病急性加重期血清炎症因子的研究[J].山西医药杂志,2018,47(23):2844-2845.[21]武金银.莫西沙星对慢性支气管炎急性发作期血气指标、内皮素-1等炎性因子水平的影响[J].安徽医药,2019,23(1):176-179.[22]唐学文,贾运涛,田晓江,等.左氧氟沙星、莫西沙星和环丙沙星上市后安全警戒信号的挖掘与评价——基于真实世界不良反应研究[J].中国新药杂志,2018,27(5):596-602.

相似文献/References:

[1]刘 岩.利奈唑胺联合莫西沙星治疗结核性脑膜炎的效果[J].医学信息,2019,32(16):131.[doi:10.3969/j.issn.1006-1959.2019.16.043]
　LIU Yan.Effect of Linezolid Combined with Moxifloxacin on Tuberculous Meningitis[J].Journal of Medical Information,2019,32(01):131.[doi:10.3969/j.issn.1006-1959.2019.16.043]
[2]崔建坤.莫西沙星序贯治疗老年社区获得性肺炎效果及对肺功能的影响[J].医学信息,2021,34(08):147.[doi:10.3969/j.issn.1006-1959.2021.08.039]
　CUI Jian-kun.Effect of Moxifloxacin Sequential Treatment of Elderly Community Acquired Pneumonia and Its Influence on Lung Function[J].Journal of Medical Information,2021,34(01):147.[doi:10.3969/j.issn.1006-1959.2021.08.039]
[3]李莎雯.注射用甲泼尼龙琥珀酸钠联合特布他林雾化吸入治疗慢性支气管炎急性发作期的效果及安全性分析[J].医学信息,2022,35(20):77.[doi:10.3969/j.issn.1006-1959.2022.20.019]
　LI Sha-wen.Effect and Safety Analysis of Methylprednisolone Sodium Succinate for Injection Combined with Terbutaline Aerosol Inhalation in the Treatment of Acute Exacerbation of Chronic Bronchitis[J].Journal of Medical Information,2022,35(01):77.[doi:10.3969/j.issn.1006-1959.2022.20.019]

更新日期/Last Update: 1900-01-01